Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      REGULATION of blood pressure; VALSARTAN; ANGIOTENSINS; HYPERTENSION; THERAPEUTICS; CARDIOVASCULAR disease treatment; CLINICAL drug trials
    • Abstract:
      The article discusses a study which compared the ability of dual-acting LCZ696 and angiotensin-receptor blocker valsartan in reducing blood pressure. The study included 1,328 patients, aged 18 to 75 years, diagnosed with mild to moderate hypertension, who were assigned to take either LCZ696 or valsartan. Study authors found that dual-acting LCZ696 is superior to valsartan in terms of providing complementary and fully additive blood pressure reduction. They concluded that LCZ696 offers a promise for hypertension and cardiovascular disease treatment.